Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 57
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
2.
Zhonghua Nan Ke Xue ; 24(1): 72-77, 2018.
Artigo em Chinês | MEDLINE | ID: mdl-30157365

RESUMO

OBJECTIVE: To observe the clinical effect and safety of the Chinese patent medicine Ningmitai Capsules (NMT) in relieving lower urinary tract symptoms (LUTS) in the patient with benign prostatic hyperplasia (BPH). METHODS: We randomly assigned 40 BPH patients to an experimental and a control group of equal number to receive oral administration of NMT at 4 capsules tid and terazosin hydrochloride tablets at 2 mg qd, respectively, both for 14 days. At 7 and 14 days after medication, we recorded and compared the International Prostate Symptoms Score (IPSS), maximum urinary flow rate (Qmax), quality of life (QoL) scores, results of urinalysis and blood routine examination, and indexes of hepatic and renal function. RESULTS: Both NMT and terazosin significantly improved the total IPSS score, the IPSS scores in the storage and voiding phases, increased Qmax and urine output, reduced post-void residual urine (PVR), and improved the QoL of the patients. The patients of the NMT group showed a better relief of incomplete bladder emptying, more improved QoL and fewer adverse reactions, while those treated with terazosin achieved a better attenuation of weak urine stream and PVR. CONCLUSIONS: NMT is safe and effective in relieving LUTS in BPH patients. Each of NMT and terazosin has its own advantages in attenuating urinary tract irritation and obstruction, but whether their combination may produce a better effect on LUTS and the specific mechanisms of NMT improving acute symptoms of BPH are yet to be further studied.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Sintomas do Trato Urinário Inferior/tratamento farmacológico , Prazosina/análogos & derivados , Hiperplasia Prostática/complicações , Agentes Urológicos/uso terapêutico , Administração Oral , Cápsulas , Quimioterapia Combinada , Humanos , Sintomas do Trato Urinário Inferior/etiologia , Masculino , Prazosina/uso terapêutico , Qualidade de Vida , Retenção Urinária/tratamento farmacológico , Micção
3.
Sci Rep ; 7(1): 14429, 2017 10 31.
Artigo em Inglês | MEDLINE | ID: mdl-29089544

RESUMO

We applied a newly introduced method, network meta-analysis, to re-evaluate the expulsion effect of drugs including tamsulosin, doxazosin, nifedipine, terazosin and rowatinex after extracorporeal shock wave lithotripsy (ESWL) as described in the literature. A systematic search was performed in Medline, Embase and Cochrane Library for articles published before March 2016. Twenty-six studies with 2775 patients were included. The primary outcome was the number of patients with successful stone expulsion. The data were subdivided into three groups according to duration of follow-up. A standard network model was established in each subgroup. In 15-day follow-up results, SUCRA outcome showed the ranking of effects was: doxazosin > tamsulosin > rowatinex > nifedipine > terazosin (88.6, 77.4, 58.6, 32.2 and 30.4, respectively). In 45-day follow-up results, SUCRA ranking was: tamsulosin > nifedipine > rowatinex (69.4, 67.2 and 62.6, respectively). In 90-day follow-up results, SUCRA ranking was: doxazosin > rowatinex > tamsulosin (84.1, 68.1 and 49.1, respectively). In conclusion, doxazosin and tamsulosin have potential to be the first choice for pharmacological therapy to promote the expulsion of urinary stone fragments after ESWL, with this doxazosin can improve the SFR in the long term, while tamsulosin may result more in accelerating the process of expulsion.


Assuntos
Litotripsia/métodos , Cálculos Urinários/tratamento farmacológico , Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Terapia Combinada , Humanos , Cálculos Renais/tratamento farmacológico , Metanálise em Rede , Nifedipino , Prazosina/análogos & derivados , Sulfonamidas/uso terapêutico , Terpenos , Resultado do Tratamento , Cálculos Ureterais/terapia
4.
Pak J Pharm Sci ; 30(1 Suppl): 289-293, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28625956

RESUMO

Benign prostatic hyperplasia (BPH) is a disease of senile age, usually occurring> 60 years of age. BPH is a disease that involves cell proliferation of the prostate. Pathological hyperplasia affects the elements of the glandular and connective tissue of the prostate. This study is designed to scrutinize the efficacy and tolerability of herbal drug Anti BPH capsule for the management of benign prostate hyperplasia (BPH), in this study we select the 100 patients in which 50 received the Anti BPH capsule and 50 received the Terazosin HCl. We use the American Urological Association BPH Symptom Score Index Questionnaire to measure the quality of life of the patients. We compare the before treatment and after treatment results for each symptom. We record the following symptoms, incomplete emptying of bladder, Frequency, Intermittency, Urgency, Weak stream, Straining, Nocturia and weight of prostate gland by USG. We compare the both drug by using paired sample t-test. The level of significance of incomplete emptying of bladder before treatment and after treatment is 0.013 in test group and 0.032 in control group. Similarly the level of significance of Frequency before treatment and after treatment in test groups in, intermittency, Urgency, Weak stream, staining, Nocturia and mean weight of prostate gland are 0.007, 0.015, 0.044, 0.012, 0.017, 0.004 and 0.020; where as in control group afford as 0.031, 0.044, 0.044, 0.032, 0.024, 0.009 and 0.035 respectively. The herbal drug Anti BPH capsule is more effective in the treatment of BPH than Allopathic medicine Terazosin HCl.


Assuntos
Cápsulas/uso terapêutico , Extratos Vegetais/uso terapêutico , Preparações de Plantas/uso terapêutico , Prazosina/análogos & derivados , Hiperplasia Prostática/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Prazosina/uso terapêutico , Próstata/efeitos dos fármacos , Qualidade de Vida , Inquéritos e Questionários
5.
Molecules ; 22(6)2017 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-28635653

RESUMO

Inhibition of apoptosis is a potential therapy to treat human diseases such as neurodegenerative disorders (e.g., Parkinson's disease), stroke, and sepsis. Due to the lack of druggable targets, it remains a major challenge to discover apoptosis inhibitors. The recent repositioning of a marketed drug (i.e., terazosin) as an anti-apoptotic agent uncovered a novel target (i.e., human phosphoglycerate kinase 1 (hPgk1)). In this study, we developed a virtual screening (VS) pipeline based on the X-ray structure of Pgk1/terazosin complex and applied it to a screening campaign for potential anti-apoptotic agents. The hierarchical filters in the pipeline (i.e., similarity search, a pharmacophore model, a shape-based model, and molecular docking) rendered 13 potential hits from Specs chemical library. By using PC12 cells (exposed to rotenone) as a cell model for bioassay, we first identified that AK-918/42829299, AN-465/41520984, and AT-051/43421517 were able to protect PC12 cells from rotenone-induced cell death. Molecular docking suggested these hit compounds were likely to bind to hPgk1 in a similar mode to terazosin. In summary, we not only present a versatile VS pipeline for potential apoptosis inhibitors discovery, but also provide three novel-scaffold hit compounds that are worthy of further development and biological study.


Assuntos
Apoptose/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Fosfoglicerato Quinase/antagonistas & inibidores , Fosfoglicerato Quinase/metabolismo , Prazosina/análogos & derivados , Inibidores de Proteínas Quinases/farmacologia , Animais , Sobrevivência Celular/efeitos dos fármacos , Bases de Dados de Compostos Químicos , Humanos , Modelos Moleculares , Simulação de Acoplamento Molecular/métodos , Células PC12 , Fosfoglicerato Quinase/química , Prazosina/química , Prazosina/metabolismo , Prazosina/farmacologia , Inibidores de Proteínas Quinases/química , Inibidores de Proteínas Quinases/metabolismo , Ratos , Bibliotecas de Moléculas Pequenas
6.
PLoS Genet ; 13(4): e1006744, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28426667

RESUMO

Degeneration and loss of lower motor neurons is the major pathological hallmark of spinal muscular atrophy (SMA), resulting from low levels of ubiquitously-expressed survival motor neuron (SMN) protein. One remarkable, yet unresolved, feature of SMA is that not all motor neurons are equally affected, with some populations displaying a robust resistance to the disease. Here, we demonstrate that selective vulnerability of distinct motor neuron pools arises from fundamental modifications to their basal molecular profiles. Comparative gene expression profiling of motor neurons innervating the extensor digitorum longus (disease-resistant), gastrocnemius (intermediate vulnerability), and tibialis anterior (vulnerable) muscles in mice revealed that disease susceptibility correlates strongly with a modified bioenergetic profile. Targeting of identified bioenergetic pathways by enhancing mitochondrial biogenesis rescued motor axon defects in SMA zebrafish. Moreover, targeting of a single bioenergetic protein, phosphoglycerate kinase 1 (Pgk1), was found to modulate motor neuron vulnerability in vivo. Knockdown of pgk1 alone was sufficient to partially mimic the SMA phenotype in wild-type zebrafish. Conversely, Pgk1 overexpression, or treatment with terazosin (an FDA-approved small molecule that binds and activates Pgk1), rescued motor axon phenotypes in SMA zebrafish. We conclude that global bioenergetics pathways can be therapeutically manipulated to ameliorate SMA motor neuron phenotypes in vivo.


Assuntos
Neurônios Motores/metabolismo , Atrofia Muscular Espinal/metabolismo , Fosfoglicerato Quinase/genética , Medula Espinal/metabolismo , Proteína 1 de Sobrevivência do Neurônio Motor/genética , Trifosfato de Adenosina/metabolismo , Animais , Axônios/metabolismo , Axônios/patologia , Modelos Animais de Doenças , Suscetibilidade a Doenças , Metabolismo Energético , Regulação da Expressão Gênica no Desenvolvimento , Humanos , Camundongos , Mitocôndrias/metabolismo , Neurônios Motores/efeitos dos fármacos , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/fisiopatologia , Fosfoglicerato Quinase/antagonistas & inibidores , Prazosina/administração & dosagem , Prazosina/análogos & derivados , Medula Espinal/crescimento & desenvolvimento , Medula Espinal/patologia , Proteína 1 de Sobrevivência do Neurônio Motor/metabolismo , Peixe-Zebra/genética , Peixe-Zebra/crescimento & desenvolvimento
7.
Zhonghua Nan Ke Xue ; 23(5): 464-467, 2017 May.
Artigo em Chinês | MEDLINE | ID: mdl-29717841

RESUMO

OBJECTIVE: To investigate the short- and long-term effects of triple acupuncture at the Qugu acupoint as an adjunctive therapy on type-Ⅲ chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS). METHODS: We equally randomized 90 CP/CPPS patients into a control and a treatment group, both treated with Levofloxacin Mesylate Tablets (0.5 g, tid) + Terazosin Hydrochloride Capsules (2 mg qd) for 4 weeks, while the latter group by triple acupuncture at the Qugu acupoint as an adjunctive therapy twice a week at the same time. Then, we followed up all the patients for 4 weeks, recorded the cases, time and rate of recurrence, obtained the scores in National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), quality of life (QoL) and Zung Depression Scale (ZDS), and compared them between the two groups of patients. RESULTS: Compared with the controls, the patients of the treatment group showed significantly decreased NIH-CPSI scores in pain (8.6 ± 2.12 vs 6.2 ± 2.25, P <0.05), micturition (5.8 ± 1.22 vs 3.1 ± 1.10, P <0.05), and QoL (6.0 ± 1.33 vs 3.4 ± 1.71, P <0.05) and ZDS score as well (43.9 ± 4.53 vs 33.6 ± 3.20, P <0.01). The recurrence rate was markedly lower while the recurrence time remarkably longer in the treatment than in the control group (15.56 vs 35.56% and ï¼»20.0 ± 2.72ï¼½ vs ï¼»12.5 ± 3.47ï¼½ d, P <0.05). CONCLUSIONS: As an adjunctive therapy, triple acupuncture at the Qugu acupoint can evidently ameliorate the clinical symptoms, enhance the curative effect of antibacterials, reduce the recurrence rate, and prolong the recurrence time in the treatment of CP/CPPS.


Assuntos
Pontos de Acupuntura , Terapia por Acupuntura/métodos , Dor Pélvica/terapia , Prostatite/terapia , Antibacterianos/uso terapêutico , Doença Crônica , Dor Crônica/terapia , Terapia Combinada , Quimioterapia Combinada/métodos , Humanos , Levofloxacino/uso terapêutico , Masculino , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Qualidade de Vida , Recidiva , Síndrome , Estados Unidos , Agentes Urológicos/uso terapêutico
8.
Zhonghua Nan Ke Xue ; 22(10): 897-901, 2016 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-29278471

RESUMO

OBJECTIVE: To investigate the effect and safety of oral Tonglin Powder in the treatment of benign prostatic hyperplasia (BPH). METHODS: We conducted a randomized controlled study on 100 BPH patients, aged 40-85 years, treated with Tonglin Powder (treatment group, n=50) or terazosin (control group, n=50), all for 3 months. Then we obtained the International Prostate Symptom Score (IPSS), quality of life score (QoL), prostate volume, postvoid residual urine volume (PVR), urine routine indexes, and liver and kidney function indexes from the patients and compared them between the two groups before and after treatment. RESULTS: The baseline data of the patients in the treatment and control groups were as follows, IPSS (22.24±7.33) vs (21.40±8.24), QoL 4 (2-6) vs 4 (2-6), prostate length 45 (30-65) vs 45 (39-65) mm, prostate width 35 (21-54) vs 36 (26-57) mm, and PVR 10 (5-100) vs 10 (10-100) ml, none with statistically significant difference between the two groups (P>0.05). After treatment, the patients of the treatment group, in comparison with those of the control, showed remarkable decreases in IPSS (11.60±6.49 vs 15.38±7.34, P=0.008) and QoL (2 ï¼»0-5ï¼½ vs 3 ï¼»1-6ï¼½, P=0.01). No statistically significant differences were observed between the treatment and control groups in prostate length (47 ï¼»38-67ï¼½ vs 47.5 ï¼»38-67ï¼½ mm), prostate width (36 ï¼»26-57ï¼½ vs 36.5 ï¼»31-57ï¼½ mm), and PVR (10 ï¼»8-100ï¼½ vs 10 ï¼»8-70ï¼½ ml) (P>0.05). The Nimodipine method of evaluation showed that the excellence rate of therapeutic effectiveness was significantly higher in the treatment than in the control group (40% vs 8%, P<0.001), and so was the total effectiveness rate (82% vs 64%, P=0.043). CONCLUSIONS: Tonglin Powder can effectively improve the symptoms of BPH, such as difficult urination, and hence the patient's quality of life.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Hiperplasia Prostática/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Qualidade de Vida , Resultado do Tratamento
9.
Zhonghua Nan Ke Xue ; 18(10): 950-2, 2012 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-23297506

RESUMO

OBJECTIVE: To evaluate the efficacy and safety of Compound Xuanju Capsule (CXC) in the treatment of chronic prostatitis with erectile dysfunction (ED). METHODS: We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0.2 g bid for 4-6 weeks and oral Terazosin at 2 mg qd for 2 months, and the latter with oral CXC once 2 capsules tid for 2 months in addition to the above. RESULTS: None of the patients had serious medication-related adverse reactions. After treatment, the control group showed significantly decreased NIH-CPSI scores and slightly increased IIEF-5 scores as compared with the baseline (16.5 +/- 5.9 vs 25.1 +/- 5.5, P < 0.05 and 13.1 +/- 5.2 vs 11.3 +/- 4.5, P > 0.05), while the treatment group exhibited significant improvement in both NIH-CPSI (13.4 +/- 5.7 vs 25.5 +/- 5.3, P < 0.05) and IIEF-5 scores (17.5 +/- 6.5 vs 10.8 +/- 3.8, P < 0.05). The total effectiveness rate for ED was significantly higher in the treatment than in the control group (74.2% vs 20%, P < 0.05). CONCLUSION: Compound Xuanju Capsule can significantly alleviate both the symptoms of chronic prostatitis and ED in the treatment of chronic prostatitis patients with ED.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Disfunção Erétil/tratamento farmacológico , Fitoterapia , Prostatite/tratamento farmacológico , Adulto , Cápsulas , Doença Crônica , Disfunção Erétil/complicações , Humanos , Levofloxacino , Masculino , Pessoa de Meia-Idade , Ofloxacino/uso terapêutico , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Prostatite/complicações , Resultado do Tratamento , Adulto Jovem
10.
Bioorg Med Chem Lett ; 21(19): 5905-9, 2011 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-21875797

RESUMO

Quantum dots (QDs) that are conjugated to small molecule derivatives of drugs and endogenous ligands may be useful tools to study the distribution and dynamic of membrane bound receptors, ion channels and transporters in live cells. In order to use these tools, it is necessary to functionalize QDs with bioactive ligands. In this paper, we successfully synthesized a ligand of α(1)-adrenoceptor that could be conjugated to QDs. In addition, the conjugation of the ligands to QDs and their biological activity were evaluated through binding assay with 30 nM QD conjugates in living human embryonic kidney 293 cells.


Assuntos
Desenho de Fármacos , Prazosina/análogos & derivados , Pontos Quânticos , Quinazolinas/química , Receptores Adrenérgicos alfa 1/metabolismo , Antagonistas de Receptores Adrenérgicos alfa 1/metabolismo , Bioensaio , Biotina/metabolismo , Avaliação Pré-Clínica de Medicamentos , Células HEK293 , Humanos , Ligantes , Estrutura Molecular , Peso Molecular , Piperazinas/metabolismo , Polietilenoglicóis/metabolismo , Prazosina/química , Prazosina/metabolismo , Ligação Proteica , Quinazolinas/metabolismo
11.
Planta Med ; 77(18): 1990-5, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21786221

RESUMO

The resistance to chemotherapeutic drugs by cancer cells is considered to be one of the major obstacles for success in the treatment of cancer. A major mechanism underlying this multidrug resistance is the overexpression of P-glycoprotein (P-gp), resulting in insufficient drug delivery to the tumor sites. A previous study has shown that stemofoline, an alkaloid isolated from Stemona burkillii, could enhance the sensitivity of chemotherapeutics in a synergistic fashion. In the present study, we have focused on the effect of stemofoline on the modulation of P-gp function in a multidrug resistant human cervical carcinoma cell line (KB-V1). The effects of stemofoline on a radiolabeled drug, [(3)H]-vinblastine, and fluorescent P-gp substrates, rhodamine 123 and calcein-AM accumulation or retention were investigated to confirm this finding. Stemofoline could increase the accumulation or retention of radiolabeled drugs or fluorescent P-gp substrates in a dose-dependent manner. For additional studies on drug-P-gp binding, P-gp ATPase activity was stimulated by stemofoline in a concentration-dependent manner. More evidence was offered that stemofoline inhibits the effect on photoaffinity labeling of P-gp with [(125)I]-iodoarylazidoprazosin in a concentration-dependent manner. These data indicate that stemofoline may interact directly with P-gp and inhibit P-gp activity, whereas stemofoline has no effect on P-gp expression. Taken together, the results exhibit that stemofoline possesses an effective MDR modulator, and may be used in combination with conventional chemotherapeutic drugs to reverse MDR in cancer cells.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/química , Adenosina Trifosfatases/química , Animais , Antineoplásicos/farmacologia , Azidas/farmacologia , Sítios de Ligação , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Resistência a Múltiplos Medicamentos , Citometria de Fluxo , Fluoresceínas/química , Corantes Fluorescentes/química , Humanos , Insetos/química , Membranas/efeitos dos fármacos , Marcadores de Fotoafinidade/química , Raízes de Plantas/química , Prazosina/análogos & derivados , Prazosina/farmacologia , Ligação Proteica , Rodamina 123/química , Stemonaceae/química , Vimblastina/farmacologia
12.
Pharmacogenet Genomics ; 21(2): 66-75, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21150813

RESUMO

OBJECTIVES: Distribution of fluoroquinolones to the retina is normally restricted by ABCG2 at the blood-retinal barrier. As the cat develops a species-specific adverse reaction to photoreactive fluoroquinolones, our goal was to investigate ABCG2 as a candidate gene for fluoroquinolone-induced retinal degeneration and blindness in cats. METHODS: Feline ABCG2 was sequenced and the consensus amino acid sequence was compared with that of 10 other mammalian species. Expression of ABCG2 in feline retina was assessed by immunoblot. cDNA constructs for feline and human ABCG2 were constructed in a pcDNA3 expression vector and expressed in HEK-293 cells, and ABCG2 expression was analyzed by western blot and immunofluorescence. Mitoxantrone and BODIPY-prazosin efflux measured by flow cytometry and a phototoxicity assay were used to assess feline and human ABCG2 function. RESULTS: Four feline-specific (compared with 10 other mammalian species) amino acid changes in conserved regions of ABCG2 were identified. Expression of ABCG2 on plasma membranes was confirmed in feline retina and in cells transfected with human and feline ABCG2, although some intracellular expression of feline ABCG2 was detected by immunofluorescence. Function of feline ABCG2, compared with human ABCG2, was found to be deficient as determined by flow cytometric measurement of mitoxantrone and BODIPY-prazosin efflux and enrofloxacin-induced phototoxicity assays. CONCLUSION: Feline-specific amino acid changes in ABCG2 cause a functional defect of the transport protein in cats. This functional defect may be owing, in part, to defective cellular localization of feline ABCG2. Regardless, dysfunction of ABCG2 at the blood-retinal barrier likely results in accumulation of photoreactive fluoroquinolones in feline retina. Exposure of the retina to light would then generate reactive oxygen species that would cause the characteristic retinal degeneration and blindness documented in some cats receiving high doses of some fluoroquinolones. Pharmacological inhibition of ABCG2 in other species might result in retinal damage if fluoroquinolones are concurrently administered.


Assuntos
Transportadores de Cassetes de Ligação de ATP/genética , Doenças do Gato/induzido quimicamente , Doenças do Gato/genética , Fluoroquinolonas/efeitos adversos , Degeneração Retiniana/veterinária , Transportadores de Cassetes de Ligação de ATP/química , Transportadores de Cassetes de Ligação de ATP/metabolismo , Sequência de Aminoácidos , Animais , Sequência de Bases , Compostos de Boro/metabolismo , Gatos , Sequência Conservada/genética , DNA Complementar/genética , Dermatite Fototóxica/complicações , Dermatite Fototóxica/genética , Dermatite Fototóxica/veterinária , Imunofluorescência , Fluoroquinolonas/química , Células HEK293 , Humanos , Mitoxantrona/farmacologia , Biologia Molecular , Dados de Sequência Molecular , Prazosina/análogos & derivados , Prazosina/metabolismo , Retina/efeitos dos fármacos , Retina/metabolismo , Retina/patologia , Degeneração Retiniana/induzido quimicamente , Degeneração Retiniana/complicações , Degeneração Retiniana/genética , Transfecção
13.
J Urol ; 183(5): 2085-9, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20303529

RESUMO

PURPOSE: Complementary and alternative medicine, including phytotherapeutic agents, or those derived from plant or herb extracts to treat symptoms, is widely accepted in the community. Men with bothersome lower urinary tract symptoms due to benign prostatic hyperplasia increasingly use such preparations. Phytotherapeutic agent quality is unregulated and in most instances the contents are unknown while erectile dysfunction and prostate cancer treatments have shown contamination with standard pharmaceuticals. Since trial results for benign prostatic hyperplasia phytotherapeutic agents are inconsistent, they may also be contaminated. Thus, we determined whether pharmacological doses of alpha-blockers and/or 5alpha-reductase inhibitors were present in a sample of phytotherapeutic agents for benign prostatic hyperplasia. MATERIALS AND METHODS: We analyzed 15 phytotherapeutic products marketed for benign prostatic hyperplasia. Only oral tablets or capsules were considered with teas, tonics and foods excluded from study. We made random purchases from shop front health stores and Internet retailers. All batches of commercial phytotherapy were analyzed by high performance liquid chromatography. Analysis was semiquantitative using extracts from alfuzosin, doxazosin, terazosin, tamsulosin, dutasteride and finasteride. RESULTS: In the 15 batches of different phytotherapeutic agents tested no interference secondary to contamination with alpha-blockers or 5alpha-reductase inhibitors was observed. CONCLUSIONS: All phytotherapeutic agents for benign prostatic hyperplasia in this study tested negative for alpha-blockers and 5alpha-reductase inhibitors. Inconsistent results in trials using phytotherapeutic agents are probably not explained by the presence of standard pharmaceuticals.


Assuntos
Antagonistas Adrenérgicos alfa/química , Contaminação de Medicamentos , Inibidores Enzimáticos/química , Fitoterapia , Hiperplasia Prostática/tratamento farmacológico , Administração Oral , Azasteroides/química , Cápsulas , Colestenona 5 alfa-Redutase/antagonistas & inibidores , Cromatografia Líquida de Alta Pressão , Doxazossina/química , Dutasterida , Finasterida/química , Humanos , Masculino , Prazosina/análogos & derivados , Prazosina/química , Quinazolinas/química , Sulfonamidas/química , Comprimidos , Tansulosina
14.
Complement Ther Med ; 18(1): 21-7, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20178875

RESUMO

OBJECTIVES: A randomised controlled trial was performed to compare the symptomatic effects on patients with benign prostatic hyperplasia (BPH) treated by two therapeutic approaches - the Western medicine (WM) and traditional Chinese medicine (TCM). METHODS: Four primary outcome measures, namely the quality of life (QOL), maximum urine flow ratio (UFR), International Prostate Symptom Score (IPSS) and prostate volumes, as well as four urethra-related and 35 non-urethra-related symptoms, were investigated to evaluate the effects on 31 BPH patients subjected to WM (Terazosin Hydrochloride Hytrin, THH) and 30 cases to TCM (herbal Saxifrage tablet, HST). The effects of both treatments are compared by the two-sample Kolmogorov-Smirnov test. The contributions of symptoms for four assessments are analysed by the logistic regression model and the Chow test. RESULTS: The effect of TCM is weaker than that of WM in the assessment of the IPSS score (p<0.05), and both treatments are similar in the prostate volumes, the maximum UFR and the QOL assessments (p>0.05), as well as in the effective number of urethra-related or non-urethra-related symptoms before and after treatment (p>0.05). By comparing the linear regression models, different urethra-related and non-urethra-related symptom patterns associated with TCM and WM therapies are detected for four assessments, especially for the prostate volume assessment (p<0.01). CONCLUSION: TCM (HST) is a potentially effective treatment in improving the QOL, prostate volumes and maximum UFR for patients with BPH, though it is less effective in ameliorating the IPSS score when compared with WM (THH). The non-urethra-related symptoms experienced by BPH patients might be one of the parameters to further achieve the tailored diagnosis and treatment for BPH.


Assuntos
Antineoplásicos/uso terapêutico , Medicina Tradicional Chinesa/métodos , Fitoterapia/métodos , Prazosina/análogos & derivados , Hiperplasia Prostática/tratamento farmacológico , Saxifragaceae , Idoso , Antineoplásicos/normas , Humanos , Modelos Logísticos , Masculino , Medicina , Medicina Tradicional Chinesa/normas , Pessoa de Meia-Idade , Fitoterapia/normas , Preparações de Plantas/farmacologia , Preparações de Plantas/uso terapêutico , Prazosina/normas , Prazosina/uso terapêutico , Próstata/fisiopatologia , Qualidade de Vida , Inquéritos e Questionários , Uretra/fisiopatologia , Micção/efeitos dos fármacos , Micção/fisiologia
15.
Urol Clin North Am ; 36(4): 537-69, vii, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19942051

RESUMO

This article examines real-life case histories of men with routine and not so routine conditions underlying lower urinary tract symptoms (LUTS), and demonstrates the utility of what has become our standard evaluation: repeated bladder diaries, urinary flow rate postvoid residual urine flow, cystoscopy, and videourodynamics, as well as the routinely used LUTS questionnaire. Each case history was sent to each of the other authors of this monograph who, on a case by case basis, answered queries and made relevant comments. The patient evaluations and case histories are discussed by top experts who have authored articles in this issue.


Assuntos
Prostatismo/diagnóstico , Prostatismo/terapia , Doenças da Bexiga Urinária/diagnóstico , Doenças da Bexiga Urinária/terapia , Antagonistas Adrenérgicos alfa/uso terapêutico , Adulto , Cistoscopia , Humanos , Masculino , Prontuários Médicos , Pessoa de Meia-Idade , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Prostatismo/fisiopatologia , Ressecção Transuretral da Próstata , Doenças da Bexiga Urinária/fisiopatologia , Urodinâmica
16.
Urologiia ; (3): 62-4, 2009.
Artigo em Russo | MEDLINE | ID: mdl-19673124

RESUMO

TUR of the prostatic gland for prostatic adenoma was made in 93 patients aged 54-81 years (mean age 64.4 +/- 7.5 years). The patients were divided into two groups. Patients of group 1 (n = 31) received no alpha-adrenoblockers, those of group 2 (n = 62) received terasosine in pre- and postoperative period. Group 2 patients demonstrated significant improvement in clinical parameters, postoperative hospital stay for them decreased by 11.3%, side effects were insignificant, their residual urine early after operation was 26.3 +/- 8.6 cm3 while 4 weeks after TUR it was 16.3 +/- 6.9 cm3. Thus, terasosine (setegis) can be recommended for use in early postoperative period after TUR of the prostate for prostatic adenoma as an effective and safe drug improving postoperative outcome.


Assuntos
Antagonistas Adrenérgicos alfa/uso terapêutico , Prazosina/análogos & derivados , Hiperplasia Prostática/tratamento farmacológico , Hiperplasia Prostática/cirurgia , Ressecção Transuretral da Próstata , Transtornos Urinários/tratamento farmacológico , Antagonistas Adrenérgicos alfa/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Esquema de Medicação , Humanos , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Prazosina/administração & dosagem , Prazosina/uso terapêutico , Hiperplasia Prostática/complicações , Qualidade de Vida , Índice de Gravidade de Doença , Resultado do Tratamento , Transtornos Urinários/etiologia
18.
Hypertension ; 51(4): 884-90, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18285617

RESUMO

Previous studies suggest that activation of the CNS melanocortin system reduces appetite while increasing sympathetic activity and arterial pressure. The present study tested whether endogenous activity of the CNS melanocortin 3/4 receptors (MC3/4-R) contributes to elevated arterial pressure in the spontaneously hypertensive rat (SHR), a model of hypertension with increased sympathetic activity. A cannula was placed in the lateral ventricle of male SHR and Wistar (WKY) rats for chronic intracerebroventricular (ICV) infusions (0.5 muL/h). Mean arterial pressure (MAP) and heart rate (HR) were recorded 24 hour/d using telemetry. After 5-day control period, rats were infused with MC3/4-R antagonist (SHU-9119, 1 nmol/h-ICV) for 12 days, followed by 5-day posttreatment period. MC3/4-R antagonism increased food intake in SHR by 90% and in WKY by 125%, resulting in marked weight gain, insulin resistance, and hyperleptinemia in SHR and WKY. Despite weight gain, MC3/4-R antagonism reduced HR in SHR and WKY ( approximately 40 bpm), while lowering MAP to a greater extent in SHR (-22+/-4 mm Hg) than WKY (-4+/-3 mm Hg). SHU9119 treatment failed to cause further reductions in MAP during chronic adrenergic blockade with propranolol and terazosin. These results suggest that endogenous activity of the CNS melanocortin system contributes to the maintenance of adrenergic tone and elevated arterial pressure in SHR even though mRNA levels for POMC and MC4R in the mediobasal hypothalamus were not increased compared to WKY. These results also support the hypothesis that weight gain does not raise arterial pressure in the absence of a functional MC3/4-R.


Assuntos
Pressão Sanguínea/fisiologia , Ingestão de Alimentos/fisiologia , Hipertensão Renal/fisiopatologia , Receptor Tipo 3 de Melanocortina/genética , Receptor Tipo 4 de Melanocortina/genética , Sistema Nervoso Simpático/fisiologia , Antagonistas Adrenérgicos alfa/farmacologia , Proteína Relacionada com Agouti/genética , Animais , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Hipertensão Renal/tratamento farmacológico , Hipotálamo/fisiologia , Masculino , Melanocortinas/metabolismo , Hormônios Estimuladores de Melanócitos/farmacologia , Neuropeptídeo Y/genética , Prazosina/análogos & derivados , Prazosina/farmacologia , Pró-Opiomelanocortina/genética , Propranolol/farmacologia , RNA Mensageiro/metabolismo , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Receptor Tipo 3 de Melanocortina/antagonistas & inibidores , Receptor Tipo 4 de Melanocortina/antagonistas & inibidores , Receptores para Leptina/genética
19.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 28(11): 998-1000, 2008 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-19213342

RESUMO

OBJECTIVE: To evaluate the effect of electroacupuncture (EA) on symptomatic benign prostatic hyperplasia (BPH). METHODS: By prospective multi-centered randomized controlled design, 93 patients with BPH were assigned to two groups, 47 in the EA group treated by EA, and 46 in the control group treated by terazosin 2 mg taken orally once every evening. EA was applied on acupoints Zhongliao (BL33) and Huiyang (BL35), for 30 min, once every two days. The total treatment period was 4 weeks for them all. The indexes for efficacy evaluation were the International Prostatic Symptom Score (IPSS), the urinary symptom bother score (BS), the maximal urinary flow rate (Qmax), the post-voided residual urine volume (PVR), and the size of prostate gland. And the times of difficulties for holding urine in 24 h (HU) and the times of night-urinating (NU) were recorded as well. RESULTS: The trial was completed in 91 patients. After 4 weeks of treatment, the IPSS lowered, Qmax increased, PVR decreased, BS score reduced, times of HU and NU lessened in both groups (P <0.01). However, comparisons between groups showed that the improvement of IPSS (6.52 +/- 0.41 vs 2.69 +/- 0.36, P < 0.01), Qmax (4.71 +/- 0.70 vs 1.75 +/- 0.55, P =0.001) and PVR (44.79 +/- 9.73 vs 16.97 +/- 4.75, P =0.012) was more significant in the EA group than in the control group respectively, but the size of prostate gland after treatment was not different between groups. CONCLUSION: EA at Zhongliao and Huiyin points can markedly improve the symptoms of difficult urination in mild or moderate patients with BPH, increase their Qmax and reduce PVR. Its efficacy is better than that of terazosin.


Assuntos
Eletroacupuntura , Hiperplasia Prostática/terapia , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Hiperplasia Prostática/tratamento farmacológico , Hiperplasia Prostática/fisiopatologia , Resultado do Tratamento , Micção/efeitos dos fármacos
20.
Zhonghua Wai Ke Za Zhi ; 45(14): 947-50, 2007 Jul 15.
Artigo em Chinês | MEDLINE | ID: mdl-17961376

RESUMO

OBJECTIVE: To compare the differences of the efficacy and different therapeutic drugs on the treatment of benign prostatic hyperplasia (BPH) in order to ensure the optimal indication for different BPH patients. METHODS: A randomized, parallel-controlled, multicenter clinical trial was conducted. From September 2002 to December 2003 906 BPH patients were enrolled into 7 therapeutic groups, including selective-adrenoceptor antagonist (terazosin, doxazosin tamsulosin and naftopidil), 5 alpha-reductase inhibitor (finasteride and epristeride) and natural product (cernilton). International Prostate Symptom Score (IPSS) and Quality of Life (QOL), uroflowmetry, total prostatic volume (TPV) and transitional zone volume and residual urine were used as efficacy criteria. RESULTS: According to the baseline, the IPSS and Qmax were significantly correlated to the prostatic volume and transitional zone volume (P < 0.01). At average follow-up of 6 months, significant improvements in IPSS, QOL, Qmax and residual urine volume were observed in each therapeutic group, and no difference in IPSS improvement was found among the groups. Prostatic volume and transitional zone volume were significant decreased in 5alpha-reductase inhibitor groups (P < 0.05). In patients with baseline TPV greater than 35.5 cm3, the improvement of Qmax was more significant than that in patients with TPV less than 35.5 cm3 in finasteride group (P < 0.01) (5.7 ml/s and 2.2 ml/s respectively), and more significant symptomatic improvements were also found in cernilton, doxazosin and naftopidil group. In each group, the improvement of symptom were more significant in patients with IPSS higher than 20 points (P < 0.01). CONCLUSIONS: Each drug observed in this study can improve the subjective and objective symptoms significantly for BPH patients, especially for patients with higher IPSS baseline. When using 5alpha-reductase inhibitor, prostatic volume can be decreased significantly and more obviously subjective and objective improvement can be found in the patients with TPV greater than 35.5 cm3.


Assuntos
Próstata/efeitos dos fármacos , Hiperplasia Prostática/tratamento farmacológico , Inibidores de 5-alfa Redutase , Antagonistas Adrenérgicos alfa/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Androstadienos/uso terapêutico , Método Duplo-Cego , Doxazossina/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Finasterida/uso terapêutico , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Naftalenos/uso terapêutico , Piperazinas/uso terapêutico , Extratos Vegetais/uso terapêutico , Prazosina/análogos & derivados , Prazosina/uso terapêutico , Próstata/patologia , Próstata/fisiopatologia , Qualidade de Vida , Secale , Sulfonamidas/uso terapêutico , Tansulosina , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA